This document provides information about the 4th annual ADC Summit 2015 conference organized by SMi that will take place from May 18-19, 2015 in London. The conference will focus on advancing antibody-drug conjugate (ADC) and radioimmunotherapy (RIT) therapies, with sessions on payload development, clinical trials of ADCs, small molecule approaches, and intellectual property issues. There will also be a half-day workshop on May 20 about the regulatory requirements and development process for ADCs.
This document provides information about the 4th annual Biobanking conference taking place on June 23-24, 2014 in London. It includes the program agenda, speaker details, registration information and sponsorship opportunities. Some of the topics to be discussed are best strategies for using biosamples, enhancing sample quality, establishing biobanking structures, sample tracking and data management systems, ethics and regulation. Registration discounts are available by February 28th or March 31st.
This document provides information about two half-day post-conference workshops on November 12, 2015 following the Advances in Cell Based Assays conference on November 10-11, 2015. Workshop A will focus on the latest generation microscopes for live cell imaging in high-throughput, high-content, and high-content analytical assays, featuring an interactive session with Nikon, UK. Workshop B will explore applying tissue engineering to develop 3D cell-based assays, focusing on generating in vitro disease models, led by Associate Professor Felicity Rose. Both workshops aim to discuss cutting-edge technologies and their applications to advance cell and tissue-based screening assays.
This document provides information about the 3rd Annual Conference on Drug Discovery Chemistry hosted by SMi Group. The conference will take place on March 18-19, 2019 in London, UK, with a half-day workshop on March 20. Key speakers will discuss topics such as novel drug modalities, targeting difficult proteins, using artificial intelligence in drug discovery, and optimizing drug discovery techniques. Attendees can learn about recent advances, network with industry leaders, and explore strategic partnerships. Discounts are available for early registration.
This document provides information about an upcoming Immuno-Oncology conference, including workshops, speakers, and program details. The conference will take place September 25-27, 2018 in London and will feature discussions on novel targeted cancer therapies. It will include workshops on strategic intelligence in immuno-oncology and the microbiome's role in cancer immunotherapy. The two-day main conference will discuss topics like immune checkpoints, oncolytic viruses, bispecific antibodies, and combination therapies. It aims to foster thought-provoking discussions in this space.
This document provides information about an upcoming conference on immunogenicity taking place June 13-14, 2016 in London. It lists the schedule, speakers, and topics to be covered over the two days. The conference will explore approaches to standardizing immunogenicity assays, unwanted immunogenicity, integrating immunogenicity risk data to predict clinical outcomes, and other topics related to assessing and reducing the immunogenicity of biotherapeutics. Registration discounts are available by March 31st or April 29th. The conference is aimed at accelerating the commercialization of next generation biotherapeutics by adopting advanced immunogenicity assessments.
Bioprocessing of Advanced Cellular Therapies CongressTony Couch
Last opportunity to get onto the programme.
Key sessions:
• Upstream process development for gene therapies
• Upstream process development for cell based therapies
• Downstream processing considerations
• Analytics - tackling measurement assurance for advanced cellular therapeutics
• Insights into Business Development and Reimbursement
• Regulatory perspectives
This document provides an agenda for the 2nd annual conference on immunogenicity taking place from June 29-30, 2015 in London. The conference will focus on understanding and modulating immunity in therapeutics, and exploring techniques to induce tolerance. It will include sessions on clinical directions, assays and assessments, with speakers from industry and academia. An interactive workshop on tools for early immunogenicity risk assessment will also be held on July 1.
This document provides information about the 9th annual conference on ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) enhancing drug quality by ADMET optimisation in discovery that will take place from June 30th to July 2nd 2014 at the Marriott Regents Park Hotel in London. Key information includes:
- Discounts are available for booking by March 31st (save £300) and April 30th (save £100).
- The conference will focus on integrating ADMET and toxicity data to enhance drug safety prediction, drug transporters, predictive toxicology, and computational/in vitro ADMET approaches.
- There will be presentations from industry leaders at companies like
This document provides information about the 4th annual Biobanking conference taking place on June 23-24, 2014 in London. It includes the program agenda, speaker details, registration information and sponsorship opportunities. Some of the topics to be discussed are best strategies for using biosamples, enhancing sample quality, establishing biobanking structures, sample tracking and data management systems, ethics and regulation. Registration discounts are available by February 28th or March 31st.
This document provides information about two half-day post-conference workshops on November 12, 2015 following the Advances in Cell Based Assays conference on November 10-11, 2015. Workshop A will focus on the latest generation microscopes for live cell imaging in high-throughput, high-content, and high-content analytical assays, featuring an interactive session with Nikon, UK. Workshop B will explore applying tissue engineering to develop 3D cell-based assays, focusing on generating in vitro disease models, led by Associate Professor Felicity Rose. Both workshops aim to discuss cutting-edge technologies and their applications to advance cell and tissue-based screening assays.
This document provides information about the 3rd Annual Conference on Drug Discovery Chemistry hosted by SMi Group. The conference will take place on March 18-19, 2019 in London, UK, with a half-day workshop on March 20. Key speakers will discuss topics such as novel drug modalities, targeting difficult proteins, using artificial intelligence in drug discovery, and optimizing drug discovery techniques. Attendees can learn about recent advances, network with industry leaders, and explore strategic partnerships. Discounts are available for early registration.
This document provides information about an upcoming Immuno-Oncology conference, including workshops, speakers, and program details. The conference will take place September 25-27, 2018 in London and will feature discussions on novel targeted cancer therapies. It will include workshops on strategic intelligence in immuno-oncology and the microbiome's role in cancer immunotherapy. The two-day main conference will discuss topics like immune checkpoints, oncolytic viruses, bispecific antibodies, and combination therapies. It aims to foster thought-provoking discussions in this space.
This document provides information about an upcoming conference on immunogenicity taking place June 13-14, 2016 in London. It lists the schedule, speakers, and topics to be covered over the two days. The conference will explore approaches to standardizing immunogenicity assays, unwanted immunogenicity, integrating immunogenicity risk data to predict clinical outcomes, and other topics related to assessing and reducing the immunogenicity of biotherapeutics. Registration discounts are available by March 31st or April 29th. The conference is aimed at accelerating the commercialization of next generation biotherapeutics by adopting advanced immunogenicity assessments.
Bioprocessing of Advanced Cellular Therapies CongressTony Couch
Last opportunity to get onto the programme.
Key sessions:
• Upstream process development for gene therapies
• Upstream process development for cell based therapies
• Downstream processing considerations
• Analytics - tackling measurement assurance for advanced cellular therapeutics
• Insights into Business Development and Reimbursement
• Regulatory perspectives
This document provides an agenda for the 2nd annual conference on immunogenicity taking place from June 29-30, 2015 in London. The conference will focus on understanding and modulating immunity in therapeutics, and exploring techniques to induce tolerance. It will include sessions on clinical directions, assays and assessments, with speakers from industry and academia. An interactive workshop on tools for early immunogenicity risk assessment will also be held on July 1.
This document provides information about the 9th annual conference on ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) enhancing drug quality by ADMET optimisation in discovery that will take place from June 30th to July 2nd 2014 at the Marriott Regents Park Hotel in London. Key information includes:
- Discounts are available for booking by March 31st (save £300) and April 30th (save £100).
- The conference will focus on integrating ADMET and toxicity data to enhance drug safety prediction, drug transporters, predictive toxicology, and computational/in vitro ADMET approaches.
- There will be presentations from industry leaders at companies like
This document provides guidance for handling inbound sales calls at a car dealership. The goal is to schedule a test drive appointment or take a message for a salesperson to follow up. It describes the types of customers that may call - those interested in a vehicle online who need price and availability details, or those who reached the wrong department. Agents are instructed to greet callers about the vehicle they inquired about online and ask probing questions to understand their needs. Calls should be transferred to the dealership or information left for follow up as needed. Detailed notes including customer contact info must be left.
Vad är mobbning? Mobbning kan vara viskningar, blickar, skratt, knuffar, slag och elaka ord. Det kan också vara taskiga sms, mejl eller inlägg på facebook eller ...
This document contains a resume for Wasim Firoz Biswas. It summarizes his educational qualifications and career objective. It lists that he has an MBA in Finance from National Institute of Technology, Durgapur, with a 6.42 CGPA. It also outlines his skills including communication, databases, and Microsoft Office. It provides details on his academic projects, internships, and extracurricular activities including participating in inter-college cricket tournaments. His career objective is to work for an organization where he can apply his knowledge and skills to become a successful professional.
Montresor takes revenge on Fortunato by luring him into the catacombs under the guise of evaluating a cask of Amontillado wine. He chains Fortunato to the wall and seals him inside, leaving him to die. The story explores themes of pride, revenge, and the destructive nature of loftiness. It is narrated from Montresor's point of view in a cold, calculating tone that reveals his ruthless character and cruel actions against his friend.
This document provides an agenda and details for the 6th annual RNA Therapeutics conference taking place on February 16-17, 2015 in London. The conference will focus on RNA interference therapeutics, antisense oligonucleotides, microRNA, and CRISPR-Cas technologies. Over the two days, there will be keynote speeches from industry leaders at Roche, AstraZeneca, and Sarepta Therapeutics, as well as academic speakers from institutions like the University of Southern Denmark and University of Oxford. Panel discussions will address collaborative models between academia and pharmaceutical companies. Business attendees will learn about maximizing returns on investment in oligonucleotide R&D. A half-day post-conference workshop
The document provides an overview and guidelines for handling inbound sales calls at a car dealership. It describes the goal of inbound sales calls as scheduling a test drive appointment or taking a message for a salesperson to follow up. It outlines two main types of inbound customers - those who saw a vehicle online and need pricing/availability info, and those who reached the wrong department. It provides tips for greeting callers, asking probing questions to understand their needs, and leaving detailed comments and selecting the proper call dispositions.
Southeast Toyota (SET) is the largest Toyota distributor in the world, headquartered in Florida. It services dealerships across 5 southeastern states. The CIC performs various call programs on SET's behalf, including contacting customers for their complimentary Toyota Care maintenance or first service appointments. These programs generate over $22 million annually in additional revenue for SET through increased service visits. The CIC aims to schedule future appointments and ensure high customer satisfaction across all call campaigns.
Toyota Certification 101 provides an overview of Toyota, its relationship with the CIC, call programs performed on Toyota's behalf, and benefits of call programs. Toyota is a Japanese automaker founded in 1937 that partners with the CIC for various customer outreach campaigns. The document outlines Toyota's history and brands like Lexus and Scion, as well as current models. It provides details on specific call campaigns aimed at scheduling service, retaining customers, and improving dealership performance. Call handlers are advised to follow scripts verbatim and represent the dealership professionally during all customer interactions.
Montresor takes revenge on Fortunato for some past insult by luring him into the catacombs under the guise of evaluating a cask of Amontillado wine. As they descend deeper underground, Montresor chains Fortunato to the wall and seals him inside with bricks, leaving him to die. The story explores themes of pride, revenge, and the destructive nature of loftiness as Montresor goes to cruel extremes to exact his vengeance on Fortunato.
The document is a product brief from Illumient that summarizes their smart off-grid solar and wind lighting solutions. It describes their lights as delivering the lowest cost of ownership and highest performance through remote monitoring and maintenance over the internet. It then provides details on the various pole, lighting, and power options available and describes the key components of their systems including solar panels, wind turbines, LED lights, control software, batteries, and more.
This document summarizes an upcoming conference on superbugs and superdrugs taking place March 25-26, 2015 in London. The conference will focus on the latest developments in antibacterial therapies, funding, and partnerships to address antibiotic resistance. Over the two days, the conference will feature speakers from industry and academia discussing topics such as new business models for antibiotic development, clinical trials of new treatments, and partnerships between government and private organizations. Attendees can choose from two pre-conference workshops on designing antimicrobials for future needs and licensing an antibiotic. The conference is aimed at professionals involved in antibiotic research, development and related fields.
This document is a program for the 3rd annual ADC Summit 2014 conference on antibody-drug conjugates taking place from May 19-21, 2014 in London. The conference will feature presentations from industry experts on topics related to developing antibody-drug conjugates, including payloads, linkers, manufacturing, and clinical trials. Attendees can learn about the latest developments and network with other professionals in the field. A pre-conference workshop on May 21st will focus on early phase development considerations for antibody-drug conjugates to support first-in-human clinical trials.
This document provides information about the ADC Summit conference to be held on May 23-24, 2016 in London. It includes:
- An agenda for the two-day conference featuring presentations and workshops on topics related to antibody-drug conjugates (ADCs), including developments, innovations, challenges and lessons learned.
- Information about two half-day post-conference workshops on May 25th regarding ADC payloads and developments in high potency API manufacturing.
- Details on registration, discounts, speakers, sponsors and exhibition opportunities for the conference.
This document provides information about the ADC Summit conference to be held on May 23-24, 2016 in London. It includes:
- An agenda for the two-day conference featuring presentations and workshops on topics related to antibody-drug conjugates (ADCs), including developments, innovations, challenges and lessons learned.
- Information about two half-day post-conference workshops on May 25th regarding ADC payloads and developments in high potency API manufacturing.
- Details on registration, discounts, speakers, sponsors and exhibition opportunities for the conference.
SMi Group's 11th annual Point of Care Diagnostics conferenceDale Butler
This document summarizes an upcoming two-day conference on point-of-care diagnostics taking place on October 27-28, 2014 in London. The conference will feature keynote speakers and panels discussing topics such as quality control of point-of-care testing, implementing point-of-care strategies, microfluidic technologies, and the future of point-of-care testing. Attendees can register online, by fax, phone, or mail. Early registration discounts are available before June 30 and July 18.
SMi Group's 8th annual Advances in Cell Based AssaysDale Butler
This document provides information about two half-day post-conference workshops on November 12, 2015 following the Advances in Cell Based Assays conference on November 10-11, 2015. Workshop A will focus on the latest generation microscopes for live cell imaging in high-throughput, high-content, and high-content analytical assays, featuring an interactive session with Nikon, UK. Workshop B will explore applying tissue engineering to develop 3D cell-based assays, focusing on generating in vitro disease models, led by Associate Professor Felicity Rose. Both workshops aim to discuss cutting-edge technologies and their applications to advance cell and tissue-based screening assays.
SMi is proud to present the 2017 19th annual Superbugs & Superdrugs conference, taking place on 20th and 21st March in Central London.
Expanding horizons on the growing threat of anti-microbial resistance for almost two decades, the flagship show in the global Superbugs portfolio of events will once again play host to an international audience of scientific leaders, funding bodies and drug discovery specialists, providing a focal point to push industry collaboration through updates on clinical advancements and investment opportunities.
This document provides information about the 8th Annual Adaptive Designs in Clinical Trials conference to be held on April 18-19, 2016 in London. The conference will focus on the latest developments and strategies in adaptive clinical trial design. It will include sessions on biomarker-driven trials, seamless phase designs, enrichment designs, and perspectives from regulators. There will also be a post-conference workshop on April 20 about using statistical software to design adaptive clinical trials. The target attendees are professionals in areas like clinical research, biostatistics, and drug development seeking to learn more about adaptive designs.
This document provides information about an upcoming conference on immunogenicity taking place from June 12-13, 2017 in London. The conference will focus on standardizing immunogenicity methods, regulatory considerations, novel approaches to reducing immunogenicity, developments for biologic drugs and immunogenicity predictions, and emerging solutions. It lists the program agenda with topics such as predictive tools for immunogenicity, reporting clinically relevant data, cut point setting, EU guidance, ADA-dependent reactions, personalizing therapy, tolerogenic nanoparticles, and a panel on human versus humanized antibodies. Speakers are from organizations like Regeneron, NIBSC, EpiVax, Novartis, Abbvie, Merck, Roche, and Immun
This document provides guidance for handling inbound sales calls at a car dealership. The goal is to schedule a test drive appointment or take a message for a salesperson to follow up. It describes the types of customers that may call - those interested in a vehicle online who need price and availability details, or those who reached the wrong department. Agents are instructed to greet callers about the vehicle they inquired about online and ask probing questions to understand their needs. Calls should be transferred to the dealership or information left for follow up as needed. Detailed notes including customer contact info must be left.
Vad är mobbning? Mobbning kan vara viskningar, blickar, skratt, knuffar, slag och elaka ord. Det kan också vara taskiga sms, mejl eller inlägg på facebook eller ...
This document contains a resume for Wasim Firoz Biswas. It summarizes his educational qualifications and career objective. It lists that he has an MBA in Finance from National Institute of Technology, Durgapur, with a 6.42 CGPA. It also outlines his skills including communication, databases, and Microsoft Office. It provides details on his academic projects, internships, and extracurricular activities including participating in inter-college cricket tournaments. His career objective is to work for an organization where he can apply his knowledge and skills to become a successful professional.
Montresor takes revenge on Fortunato by luring him into the catacombs under the guise of evaluating a cask of Amontillado wine. He chains Fortunato to the wall and seals him inside, leaving him to die. The story explores themes of pride, revenge, and the destructive nature of loftiness. It is narrated from Montresor's point of view in a cold, calculating tone that reveals his ruthless character and cruel actions against his friend.
This document provides an agenda and details for the 6th annual RNA Therapeutics conference taking place on February 16-17, 2015 in London. The conference will focus on RNA interference therapeutics, antisense oligonucleotides, microRNA, and CRISPR-Cas technologies. Over the two days, there will be keynote speeches from industry leaders at Roche, AstraZeneca, and Sarepta Therapeutics, as well as academic speakers from institutions like the University of Southern Denmark and University of Oxford. Panel discussions will address collaborative models between academia and pharmaceutical companies. Business attendees will learn about maximizing returns on investment in oligonucleotide R&D. A half-day post-conference workshop
The document provides an overview and guidelines for handling inbound sales calls at a car dealership. It describes the goal of inbound sales calls as scheduling a test drive appointment or taking a message for a salesperson to follow up. It outlines two main types of inbound customers - those who saw a vehicle online and need pricing/availability info, and those who reached the wrong department. It provides tips for greeting callers, asking probing questions to understand their needs, and leaving detailed comments and selecting the proper call dispositions.
Southeast Toyota (SET) is the largest Toyota distributor in the world, headquartered in Florida. It services dealerships across 5 southeastern states. The CIC performs various call programs on SET's behalf, including contacting customers for their complimentary Toyota Care maintenance or first service appointments. These programs generate over $22 million annually in additional revenue for SET through increased service visits. The CIC aims to schedule future appointments and ensure high customer satisfaction across all call campaigns.
Toyota Certification 101 provides an overview of Toyota, its relationship with the CIC, call programs performed on Toyota's behalf, and benefits of call programs. Toyota is a Japanese automaker founded in 1937 that partners with the CIC for various customer outreach campaigns. The document outlines Toyota's history and brands like Lexus and Scion, as well as current models. It provides details on specific call campaigns aimed at scheduling service, retaining customers, and improving dealership performance. Call handlers are advised to follow scripts verbatim and represent the dealership professionally during all customer interactions.
Montresor takes revenge on Fortunato for some past insult by luring him into the catacombs under the guise of evaluating a cask of Amontillado wine. As they descend deeper underground, Montresor chains Fortunato to the wall and seals him inside with bricks, leaving him to die. The story explores themes of pride, revenge, and the destructive nature of loftiness as Montresor goes to cruel extremes to exact his vengeance on Fortunato.
The document is a product brief from Illumient that summarizes their smart off-grid solar and wind lighting solutions. It describes their lights as delivering the lowest cost of ownership and highest performance through remote monitoring and maintenance over the internet. It then provides details on the various pole, lighting, and power options available and describes the key components of their systems including solar panels, wind turbines, LED lights, control software, batteries, and more.
This document summarizes an upcoming conference on superbugs and superdrugs taking place March 25-26, 2015 in London. The conference will focus on the latest developments in antibacterial therapies, funding, and partnerships to address antibiotic resistance. Over the two days, the conference will feature speakers from industry and academia discussing topics such as new business models for antibiotic development, clinical trials of new treatments, and partnerships between government and private organizations. Attendees can choose from two pre-conference workshops on designing antimicrobials for future needs and licensing an antibiotic. The conference is aimed at professionals involved in antibiotic research, development and related fields.
This document is a program for the 3rd annual ADC Summit 2014 conference on antibody-drug conjugates taking place from May 19-21, 2014 in London. The conference will feature presentations from industry experts on topics related to developing antibody-drug conjugates, including payloads, linkers, manufacturing, and clinical trials. Attendees can learn about the latest developments and network with other professionals in the field. A pre-conference workshop on May 21st will focus on early phase development considerations for antibody-drug conjugates to support first-in-human clinical trials.
This document provides information about the ADC Summit conference to be held on May 23-24, 2016 in London. It includes:
- An agenda for the two-day conference featuring presentations and workshops on topics related to antibody-drug conjugates (ADCs), including developments, innovations, challenges and lessons learned.
- Information about two half-day post-conference workshops on May 25th regarding ADC payloads and developments in high potency API manufacturing.
- Details on registration, discounts, speakers, sponsors and exhibition opportunities for the conference.
This document provides information about the ADC Summit conference to be held on May 23-24, 2016 in London. It includes:
- An agenda for the two-day conference featuring presentations and workshops on topics related to antibody-drug conjugates (ADCs), including developments, innovations, challenges and lessons learned.
- Information about two half-day post-conference workshops on May 25th regarding ADC payloads and developments in high potency API manufacturing.
- Details on registration, discounts, speakers, sponsors and exhibition opportunities for the conference.
SMi Group's 11th annual Point of Care Diagnostics conferenceDale Butler
This document summarizes an upcoming two-day conference on point-of-care diagnostics taking place on October 27-28, 2014 in London. The conference will feature keynote speakers and panels discussing topics such as quality control of point-of-care testing, implementing point-of-care strategies, microfluidic technologies, and the future of point-of-care testing. Attendees can register online, by fax, phone, or mail. Early registration discounts are available before June 30 and July 18.
SMi Group's 8th annual Advances in Cell Based AssaysDale Butler
This document provides information about two half-day post-conference workshops on November 12, 2015 following the Advances in Cell Based Assays conference on November 10-11, 2015. Workshop A will focus on the latest generation microscopes for live cell imaging in high-throughput, high-content, and high-content analytical assays, featuring an interactive session with Nikon, UK. Workshop B will explore applying tissue engineering to develop 3D cell-based assays, focusing on generating in vitro disease models, led by Associate Professor Felicity Rose. Both workshops aim to discuss cutting-edge technologies and their applications to advance cell and tissue-based screening assays.
SMi is proud to present the 2017 19th annual Superbugs & Superdrugs conference, taking place on 20th and 21st March in Central London.
Expanding horizons on the growing threat of anti-microbial resistance for almost two decades, the flagship show in the global Superbugs portfolio of events will once again play host to an international audience of scientific leaders, funding bodies and drug discovery specialists, providing a focal point to push industry collaboration through updates on clinical advancements and investment opportunities.
This document provides information about the 8th Annual Adaptive Designs in Clinical Trials conference to be held on April 18-19, 2016 in London. The conference will focus on the latest developments and strategies in adaptive clinical trial design. It will include sessions on biomarker-driven trials, seamless phase designs, enrichment designs, and perspectives from regulators. There will also be a post-conference workshop on April 20 about using statistical software to design adaptive clinical trials. The target attendees are professionals in areas like clinical research, biostatistics, and drug development seeking to learn more about adaptive designs.
This document provides information about an upcoming conference on immunogenicity taking place from June 12-13, 2017 in London. The conference will focus on standardizing immunogenicity methods, regulatory considerations, novel approaches to reducing immunogenicity, developments for biologic drugs and immunogenicity predictions, and emerging solutions. It lists the program agenda with topics such as predictive tools for immunogenicity, reporting clinically relevant data, cut point setting, EU guidance, ADA-dependent reactions, personalizing therapy, tolerogenic nanoparticles, and a panel on human versus humanized antibodies. Speakers are from organizations like Regeneron, NIBSC, EpiVax, Novartis, Abbvie, Merck, Roche, and Immun
SMi Group's 7th annual Biosimilars Europe 2016 conferenceDale Butler
This document provides information about two pre-conference workshops for the 7th Annual Biosimilars Europe conference.
The first workshop focuses on maximizing intellectual property and regulatory rights related to biosimilars. It will cover topics like regulatory data protection, orphan drug exclusivity, supplementary protection certificates, and pediatric rewards. The workshop leaders are partners at Bristows LLP.
The second workshop examines how the payer environment for biosimilars is evolving. It will provide insight into pricing, reimbursement, and formulary access processes. Case studies will also be presented on successful biosimilar launches. The workshop leader is the director of RJW & Partners Ltd, a pricing and market
Providing a focal point to push industry collaboration through updates on clinical advancements and investment opportunities, SMi presents the 20th annual Superbugs & Superdrugs conference which will return to Central London on 19th and 20th March 2018.
The threat of AMR is regularly making front page news but what is the industry actually doing? Are drug manufacturers any closer to finding a solution and how is the government helping? These will be just some of the questions answered through powerful keynote addresses delivered by an expert panel of scientific leaders, drug discovery specialists and government bodies such as MHRA and DNDi.
This document provides information about the 20th Annual Superbugs & Superdrugs conference on tackling antimicrobial resistance that will take place on March 19-21, 2018 in London. The conference will feature presentations on funding and regulatory approaches for new antibiotic development, strategies to combat resistant pathogens, and research on novel antibiotic candidates and alternatives. A half-day workshop on March 21st will provide an overview of using animal models in pre-clinical drug development.
The document advertises and provides an agenda for the 6th Annual Conference on Pharmaceutical Microbiology taking place January 17-19, 2017 in London. It will feature presentations and workshops on topics such as endotoxin testing, rapid microbial detection methods, environmental monitoring, and contamination control. Registration discounts are available before certain dates.
This document provides information about the "In Vitro Diagnostics: Oncology & Infectious Diseases Conference" being held on November 9-10, 2016 in London. The conference will bring together professionals from hospitals, reference laboratories, and the IVD industry to discuss potential growth in oncology and infectious disease diagnostics and related challenges. Over the two days, the conference will feature keynote presentations, panel discussions, and case studies on topics like emerging regulations, novel cancer markers, rapid testing for infectious diseases, and quality control of point-of-care testing.
After the success of the previous edition - Bioprocessing of Advanced Cellular Therapies Congress 2016, MarketsandMarkets is pleased to announce the 2nd Annual Bioprocessing of Advanced Cellular Therapies Congress in London, UK.
Research Organizations and Pharma companies have been investing big time into the promise of cellular therapies and all signs point to the need to accelerate the process of moving from lab to patient using advanced manufacturing processes and solutions to commercialization.
With this objective, making the shift from manual processes to automation, bridging the gap between research lab and market place, and using novel and advanced technologies will be the key aspects for manufacturers to answer the challenge of scale-out.
The 2nd Annual Bioprocessing of Advanced Cellular Therapies Congress taking place on the 8th and 9th June, 2017 in London, UK focuses on this holistic approach by discussing the next generation bioprocessing, strategies, technologies and solutions to work together for this constantly evolving field.
This document provides information on two pre-conference workshops at the "Superbugs & Superdrugs" conference on combating antimicrobial resistance.
The first workshop discusses rapid diagnostic tools for infectious diseases, focusing on tracking emerging infections, state-of-the-art diagnostic methods, mobile applications, and challenges in diagnosis.
The second workshop examines how antimicrobial copper touch surfaces can improve patient outcomes and reduce costs by lowering healthcare-associated infections and antimicrobial resistance. It will evaluate the evidence supporting copper's use and discuss cost-benefit analysis and practical implementation.
This document provides information on two pre-conference workshops at the "Superbugs & Superdrugs" conference on combating antimicrobial resistance.
The first workshop discusses rapid diagnostic tools for infectious diseases, focusing on tracking emerging infections, state-of-the-art diagnostic methods, mobile applications, and challenges in diagnosis.
The second workshop examines making materials like copper touch surfaces in healthcare settings to improve patient outcomes and reduce costs by lowering infection rates and antimicrobial resistance. It will evaluate the evidence for copper's antimicrobial efficacy and cost-benefit analysis.
This document provides information about the 6th annual conference on chronic obstructive pulmonary disease (COPD) being held on October 20-21, 2014 in London. The conference will feature talks from industry and clinical experts on topics related to COPD treatment and management, including regulatory issues, comorbidities, exacerbations, clinical trial design, biomarkers, phenotyping, and the patient experience. An optional half-day post-conference workshop on October 22 will provide an introduction to COPD best practices for nurses and other clinical staff.
SMi Group's Superbugs and Superdrugs 2020 conferenceDale Butler
This document provides information about the Superbugs & Superdrugs conference on March 30-31, 2020 in London. The conference will focus on non-traditional approaches to fighting antimicrobial resistance and will feature speakers from companies and organizations working on alternatives to antibiotics, including those developing antibacterial proteins, agents that neutralize bacterial virulence, direct lytic agents, and immunomodulatory therapies. It provides details on the agenda, speakers, workshops, registration and sponsorship opportunities.
SMi Group's Superbugs and Superdrugs 2020 conference
P-139_ADC Summit
1. SMi presents the 4th annual…
PLUS INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOP
Wednesday 20th May 2014, Holiday Inn Bloomsbury Hotel, London, UK
ADCs: A Journey Through Development
Workshop leaders: Dr Richard Turner, Principal Consultant, Natalie Thomas, Consultant, Simon Bishop, Associate Consultant, BioDesk
8.30am - 12.30pm
18 -19
MAY
2015Holiday Inn Bloomsbury Hotel, London, UK
ADC Summit 2015
Elevating ADCs to peak performance in the clinic
www.drugconjugates.com
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
ACADEMIC & GROUP DISCOUNTS AVAILABLE
REGISTER BY THE 27TH FEBRUARY AND SAVE £300 • REGISTER BY THE 31ST MARCH AND SAVE £100
CONFERENCE CHAIRS:
Mahendra Deonarain, Chief Science Officer,
Antikor Biopharma Ltd.
David Thurston, Professor of Drug Discovery
King’s College London
KEY SPEAKERS INCLUDE:
Angela Romanelli, Senior Director,
Biomarkers ImmunoGen, Inc
Christophe Bonny, Chief Scientific Officer,
Bicycle Therapeutics Limited
Klaus Bosslet, Head Discovery Oncology, Pharma
Research & Early Development, Roche Innovation
Centre Penzberg
Iontcho Vlahov, Vice President of Discovery
Chemistry, Endocyte Inc.
Vijay Chudasama, Research Associate, University
College London
BUSINESS BENEFITS FOR 2015:
• Hear more about the payload developments
• Receive updates on ADCs in clinical trials
• Learn more about biodistribution and tumour
penetrations
• Aim for improvement of the therapeutic index
• Discover strategies for effective targeting and
managing ADC off-target toxicities
• Understand the status of the development of novel
binding moieties
@SMIPHARM
2. Register online at: www.drugconjugates.com • Alternatively fax y
ADC Summit 2015
Day One | Monday 18th May 2015
8.30 Registration & Coffee
9.00 Chairman's Opening Remarks
Mahendra Deonarain, Chief Science Officer, Antikor Biopharma Ltd.
ADVANCING ADC/RIT THERAPIES - PART 1
OPENING ADDRESS
9.10 Biomarkers: Improving drug development success by linking
ADC therapy to the right patient
•Translating our biological understanding into successful
development of meaningful therapies for patients through
Biomarkers
•Targeting antigen expression is only the starting point, it is
necessary but not sufficient
•Thinking beyond payload delivery: How does tumour
biology impact sensitivity to the ADC payload?
•Building the right biomarker test: The right assay on the right
sample is critical for enabling selection of the right patient
in the clinic
Angela Romanelli, Senior Director of Biomarkers, ImmunoGen, Inc.
9.50 Designing novel warheads for targeted therapies: Efficient strategies
for making natural tubulysins, analogs, and their conjugates
•Any tubulysin is too toxic to be used as antineoplastic
agent itself; instead, they are excellent candidates for the
design of ligand-drug conjugates for cancer targeting
•New methodologies for the synthesis of natural tubulysins
and their analogs
•Design of new tubulysin analogs with improved cytotoxicity
and stability profiles
Iontcho Vlahov, Vice President of Discovery Chemistry,
Endocyte, Inc.
10.30 Morning Coffee
11.00 RG7787, a Mesothelin-binding Pseudomonas exotoxin-based
cytolytic fusion protein
•Pay load delivery
•Tumour selective protein synthesis inhibition and impact on
immune-suppression in tumour mass
•In vitro and in vivo potency and efficacy on very slowly
growing large tumours
•Recombinant fusion protein as advantageous alternative
technology compared to ADCs
Klaus Bosslet, Head Discovery Oncology, Pharma Research
& Early Development, Roche Innovation Centre Penzberg
11.40 Arming disease-targeting ligands with cytokines and with
cytotoxic drugs
•Use of highly validated vascular targeting antibodies for
pharmacodelivery applications.
•Antibody-cytokine fusions: From the bench to the clinic
•Cancer cures with non-internalising antibodies and low-
molecular weight ligands
Giulio Casi, Head of Targeted Cytotoxics Development,
Philochem AG
12.20 Networking Lunch
A MATTER OF SIZE: EXPLORING THE SMALL
KEYNOTE ADDRESS
1.20 High affinity bicyclic peptides:
Application to payloads in oncology
•Scaffold-constrained bicyclic peptides (bicycles) show
target-binding properties similar to antibodies, but in a
100-fold smaller format
•Bicycles penetrate tumours rapidly, delivering high
concentrations of payloads over hours, thus allowing
efficient tumour killing while minimizing systemic toxin exposure
•In vivo POC data using different targets and payloads will
be presented
Christophe Bonny, Chief Scientific Officer,
Bicycle Therapeutics Limited
2.00 The Nanobody® platform: Opportunities for next generation
drug conjugates
•Nanobodies are clinically validated small antibody
fragments derived from heavy-chain only camelid antibodies
•Explore the formatting flexibility allowing full control over
valency and multi-specificity
•Multiple conjugation chemistries possible
•Understand the manufacturing properties
Carlo Boutton, Director of Technology, Ablynx
2.40 Seriously? Folic acid can replace an antibody for targeting
potent warheads to tumours?
•The folate receptor is a tumour biomarker target
•What are small molecule drug conjugates (SMDC)?
•Use of companion imaging for selection of biomarker
positive patients
•16 years of SMDC clinical development
Christopher P. Leamon, VP, Research, Endocyte, Inc.
3.20 Afternoon Tea
3.50 Round Table Discussion: A matter of size: Is the future small?
•Does size matter?
•What size do you need and why?
•How best can you use the consequences of size?
•Discuss the data that is available to prove it
Peter Bach, Director, BioPharmaLogic Ltd.
4.20 Can You Handle Highly Potent Compounds Safely?
Are You Sure?
•Biological and chemical substance occupational hazards
•Facilities, features and equipment for handling ADC
components
•How do you know if it’s safe for your workers?
•Integration of health and safety into ADC projects
Justin Mason-Home, Managing Director, SafeBridge Europe
5.00 Using IP to benefit from ADC technologies
•Types of patent protection available for ADC
technologies
•Data requirements for ADC patents and when to file
•Freedom to operate challenges for ADC
•How to benefit from IP transactions - legal challenges and
opportunities
James Legg, Patent Attorney, Boult Wade Tennant
5.20 Chairman's Closing Remarks and Close of Day One
Want to know how you can get involved?
Interested in promoting your services to
this market?
Contact Sarah Watson, SMi Marketing on
+44 (0) 20 7827 6134,
or email: swatson@smi-online.co.uk
SAFETY
FOCUS
KEYNOTEADDRESS
IP
FOCUS
3. your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
ADC Summit 2015
Day Two | Tuesday 19th May 2015
Supported by
8.30 Registration & Coffee
9.00 Chairman's Opening Remarks
David Thurston, Professor of Drug Discovery, King’s College
London
ADVANCING ADC/RIT THERAPIES - PART 2
KEYNOTE ADDRESS
9.10 The onward march of ADCs – How near the end are we?
•How do ADC technologies compare to other types of
anticancer therapies?
•What are the pros and cons of ADCs vs. other therapies?
•What are the likely new developments in ADC technologies
to help them stay ahead?
•What are the major competitors for ADCs in the coming
decades?
David Thurston, Professor of Drug Discovery, King’s College
London
9.50 Small is beautiful-antibody-targeted nanomedicines
•Nanomedicine is a rapidly developing field of
macromolecular drug development
•Advances in industrial production mean that more of these
experimental agents can be translated to the clinic
•Antibodies can modify the characteristics of
nanomedicines and improve therapeutic effects
•Recent work in the field from ourselves and others will be
discussed, highlighting how antibody-nanoparticles may
represent a novel ADC platform
Chris Scott, Chair of Pharmaceutical Biosciences, Queens
University Belfast
10.30 Morning Coffee
11.00 Opti-linked antibody fragments as ADCs
•Optimizing single chain Fvs for bioconjugation
•High DAR
•Maintaining good PK
•Ensuring good QA
Mahendra Deonarain, Chief Scientific Officer, Antikor
Biopharma Ltd
11.40 From modified peptides to modified proteins:
New approaches to immunological recognition
•Application of sortase as a convenient approach to
quantitative modification of proteins
•Alternative approaches to the generation of multicyclic
peptides
•Selection and application of affimers as alternatives to
antibodies in diagnostic applications.
Michael Webb, Associate Professor, University of Leeds
12.20 Networking Lunch
LINKING AND LOADING
1.20 Robust disulfide bridging reagents enable delivery of a
well-characterised and multi-functional ADC platform
•Homogeneous ADCs
•Site-selective modification
•Bispecifics
•Orthogonal click functionalisation
Vijay Chudasama, Research Associate, University College London
2.00 Click chemistry-triggered activation of ADCs in vivo
•New linker concept to expand the range of ADC targets to
poorly internalizing receptors, extracellular matrix
constituents and stroma
•ADC administration followed by chemical probe that reacts
with the linker on the tumour-bound ADC, releasing the
drug in the extracellular matrix
•Maximized bystander effect: Potentially advantageous in
heterogeneous or poorly penetrated tumours
•Proof of principle data in tumour-bearing mice with anti-
TAG72 ADC comprising CC49 mAb and model drug
doxorubicin
Marc Robillard, CEO, Tagworks Pharmaceuticals
2.40 Sortase-mediated antibody conjugation (SMAC™):
Generation of homogeneous, site-specifically conjugated
antibody drug conjugates
•Sortase enzymes provide a robust and efficient means to
attach toxic payloads to antibodies.
•Highly site-specific conjugation yields homogenous drug
product with defined efficacy, PK properties and safety
profile.
•Peptide-based linker structure circumvents IP issues and is
expected to provide superior serum stability.
•Production of dual payload ADCs may help address
resistance and provide opportunity to tackle tumour
heterogeneity and quiescence
Roger Beerli, Vice President Research & Development,
NBE-Therapeutics AG
3.20 Afternoon Tea
4.00 Clinical development of ADCs: The EU landscape, trial design
and the impact of the new clinical trial regulation
•Overview of the landscape of clinical studies on ADCs in
Europe
•Clinical trial design considerations: Patient population,
endpoint selection, comparator choice, dose regimen
selection.
•The impact of implementation of the Clinical Trial
Regulation on conduct of clinical studies in Europe
•Regulatory strategies in Europe to expedite time to market
Natalie Thomas, Consultant, Clinical Network Services (UK) Ltd
4.20 Chairman’s Closing Remarks and Close of Day Two
David Thurston, Professor of Drug Discovery, King’s College
London
4. HALF-DAY POST-CONFERENCE WORKSHOP
Wednesday 20th May 2014
8.30am - 12.30pm
Holiday Inn Bloomsbury Hotel, London, UK
ADCs: A Journey Through Development
Workshop Leaders:
Dr Richard Turner, Principal Consultant, BioDesk
Dr Natalie Thomas, Consultant, BioDesk
Dr Simon Bishop, Associate Consultant, BioDesk
Overview of workshop:
This workshop will provide attendees with an overview of
data requirements for ADCs through the development
lifecycle, outlining the key CMC challenges and mitigation
strategies for the product types, and first-in-man enabling
preclinical development activities to ensure a smooth
transition from bench to bedside. Clinical study designs from
Phase 1 will be discussed through the use of case studies. The
workshop will then take attendees on a journey through the
additional data requirements to support Phase II and III
clinical development. At each stage the differences in data
requirements between the US and EU will be discussed. The
final component of the workshop will introduce the route to
ultimate approval of an ADC in the US and EU.
Why should delegates attend this workshop:
Delegates will gain an understanding of:
• Regulatory and product development requirements for
entry in to the clinical and marketing authorisation
• Common pitfalls and mitigation strategies in ADC
development to allow anticipation of regulators’
concerns at clinical trial application and marketing
authorisation application stages
• Regulatory requirement distinctions between the US and
EU, and regulatory options available to expedite time to
market
Programme
8.30 Registration and coffee
9.00 Opening Remarks
9.15 CMC Development: ADC Specifics
10.15 Enabling First-in-Human Studies
• Pre-clinical data requirements
• Trial design to maximise knowledge gained from
early stage clinical studies
10.45 Coffee break
11.15 Beyond Phase I Clinical Studies
• Clinical case studies – successful and less
successful approaches.
• Key recommendations for trial design to maximise
the likelihood of success
11.45 Key regulatory drivers for an expedited global
development
• Regulatory considerations for a global
development program including key differences
for US and EU approvals
• Regulatory strategies to maximise efficiency to
market
12.15 Closing remarks
12.30 End of workshop
About the workshop hosts:
Dr Richard Turner, BioDesk's Principal Consultant in the UK
office, has been working in biopharmaceutical
development for over 20 years. Richard is a former
pharmaceutical and scientific assessor at the Medicines
Control Agency (now known as the UK MHRA) and has
worked in senior Regulatory positions in a number of
biopharmaceutical development companies and
consultancies including Daiichi Sankyo, Lonza Biologics, ERA
Consulting, Elan and Antisoma.
Dr Natalie Thomas is a Consultant with CNS (UK) and has
over ten years’ pharmaceutical industry and consulting
experience, initially in early stage oncology drug
development and more recently in regulatory affairs.
Natalie has worked on products at all stages of
development, supporting companies from discovery
through to marketing authorisation.
Dr Simon Bishop is an Associate Consultant with three years’
experience in technical writing. At CNS, Simon works with
clinical documentation, including protocols, Investigator’s
Brochures and study reports, marketing authorisation
applications and regulatory documentation regarding
paediatrics and orphan drugs. Simon has a PhD in
developmental neurobiology and previously worked for the
Nature Publishing Group as a scientific literature editor.
About the Clinical Network Services:
Clinical Network Services (CNS) is a
uniquely integrated service group focused
on product development headquartered
in Australia with offices in New Zealand,
the UK and the USA. Through BioDesk we
provide a comprehensive range of services in the strategic
planning and delivery of CMC/non-clinical development
programs, then, leveraging our extremely pragmatic
regulatory environment, we can rapidly initiate phase 1 & 2
clinical trials in Australia/New Zealand.
5. SMI'S PHARMACEUTICAL
PORTFOLIO 2015
SPONSORSHIP AND EXHIBITION
OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising
and branding packages, uniquely tailored
to complement your company’s marketing
strategy.
Prime networking opportunities exist to entertain,
enhance and expand your client base within the
context of an independent discussion specific to
your industry.
Should you wish to join the increasing
number of companies benefiting from
sponsoring our conferences please call:
Alia Malick on +44 (0) 20 7827 6168 or
email: amalick@smi-online.co.uk
FEBRUARY
Parallel Trade
9th – 10th February 2015
Holiday Inn Regents Park, London
Advances and Progress in Drug Design
16th – 17th February 2015
Marriott Regents Park, London
RNAi Therapeutics
16th – 17th February 2015
Marriott Regents Park, London
MARCH
Superbugs & Superdrugs – A focus on
Antibacterials
25th – 26th March 2015
Holiday Inn Regents Park, London
Paediatric Clinical Trials
25th – 26th March
Holiday Inn Regents Park, London
APRIL
Asthma & COPD
13th – 14th April 2015
Holiday Inn Regents Park, London
Controlled Release
20th – 21st April 2015
Marriott Regents Park, London
Adaptive Designs
20th – 21st April 2015
Marriott Regents Park, London
Pre Filled Syringes USA
27th – 28th April 2015
Renaissance Woodbridge, Iselin, USA
Lyophilisation and Freeze Drying USA
29th – 30th April 2015
Renaissance Woodbridge, Iselin, USA
MAY
Pharmacovigilance, Drug Safety
& Risk Management
11th – 12th May 2015
Holiday Inn Regents Park, London
Pain Therapeutics
18th – 19th May 2015
Holiday Inn Bloomsbury, London
ADC Summit 2015
18th – 19th May 2015
Holiday Inn Bloomsbury, London
Clinical Trial Logistics
20th – 21st May 2015
Marriott Regents Park, London
JUNE
ADMET
29th – 30th June 2015
Marriott Regents Park, London
6. FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor
South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK
ADC SUMMIT 2015
Conference: Monday 18th May & Tuesday 19th May 2015, Holiday Inn Bloomsbury Hotel, London, UK Workshop: Wednesday 20th May 2015, London
4 WAYS TO REGISTER
www.drugconjugates.com
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk
Payment: If payment is not made at the time of booking, then an invoice will be issued and must be
paid immediately and prior to the start of the event. If payment has not been received then credit
card details will be requested and payment taken before entry to the event. Bookings within 7 days
ofeventrequirepaymentonbooking.AccesstotheDocumentPortalwillnotbegivenuntilpayment
has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send a
substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing
that cancellation is made in writing and received at least 28 days prior to the start of the event.
Regretfully cancellation after this time cannot be accepted. We will however provide the
conferences documentation via the Document Portal to any delegate who has paid but is unable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to
provide documentation in these circumstances. We cannot accept cancellations of orders placed
for Documentation or the Document Portal as these are reproduced specifically to order. If we have
to cancel the event for any reason, then we will make a full refund immediately, but disclaim any
further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other
products and services. Unless you tick here □we may also share your data with third parties offering
complementary products or services. If you have any queries or want to update any of the data that
we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit
our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the
attached letter.
Unique Reference Number
Our Reference LVP-139
Terms and Conditions of Booking
DELEGATE DETAILS
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
VENUE Holiday Inn Bloomsbury Hotel, Coram Street, London, WC1N 1HT, UK
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712
□ Book by 27th February 2015 to receive £300 off the conference price
□ Book by 31st March 2015 to receive £100 off the conference price
EARLY BIRD
DISCOUNT
Payment must be made to SMi Group Ltd, and received before the event, by one of
the following methods quoting reference P-139 and the delegate’s name. Bookings
made within 7 days of the event require payment on booking, methods of payment
are below. Please indicate method of payment:
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
Card Billing Address (If different from above):
DOCUMENTATION
I cannot attend but would like to purchase access to the following Document
Portal/paper copy documentation Price Total
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
PAYMENT
VAT
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on
Document portal and literature distribution for all UK customers and for those EU Customers
not supplying a registration number for their own country here.
______________________________________________________________________________________________
CONFERENCE PRICES
I would like to attend: (Please tick as appropriate) Fee Total
□ Conference and Workshop £2098.00 +VAT £2517.60
□ Conference only £1499.00 +VAT £1798.80
□ Workshop only £599.00 +VAT £718.80
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
The conference fee includes refreshments, lunch, conference papers, and access to the
Document Portal. Presentations that are available for download will be subject to
distribution rights by speakers. Please note that some presentations may not be available
for download. Access information for the document portal will be sent to the e-mail
address provided during registration. Details are sent within 24 hours post conference.